Rocavorexant

Rocavorexant ( ; developmental code names C4X-3256 and INDV-2000) is an orexin OX 1 receptor antagonist which is under development for the treatment of opioid-related disorders and other substance-related disorders.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Rocavorexant ( ; developmental code names C4X-3256 and INDV-2000) is an orexin OX 1 receptor antagonist which is under development for the treatment of opioid-related disorders and other substance-related disorders. It is taken orally. The drug is under development by C4X Discovery and/or Indivior.

As of May 2026, development for all indications has been suspended. The drug has reached phase 2 clinical trials for opioid-related disorders and phase 1 trials for substance-related disorders.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372045974 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.